GSK plc Buys Back Own Shares

Ticker: GLAXF · Form: 6-K · Filed: Dec 16, 2025 · CIK: 1131399

Gsk PLC 6-K Filing Summary
FieldDetail
CompanyGsk PLC (GLAXF)
Form Type6-K
Filed DateDec 16, 2025
Risk Levellow
Pages10
Reading Time12 min
Sentimentneutral

Sentiment: neutral

Topics: share-buyback, transaction

Related Tickers: BNP

TL;DR

GSK is buying back its own stock via BNP Paribas.

AI Summary

On December 16, 2025, GSK plc announced through its broker, BNP Paribas SA, that it purchased a certain number of its own ordinary shares. The filing does not specify the exact number of shares or the total dollar amount spent on the transaction.

Why It Matters

Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.

Risk Assessment

Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.

Key Players & Entities

  • GSK plc (company) — The company making the share repurchase.
  • BNP Paribas SA (company) — The broker executing the share repurchase on behalf of GSK plc.
  • 31¼ pence (dollar_amount) — Nominal value of the ordinary shares being repurchased.

FAQ

What was the specific number of GSK plc ordinary shares purchased?

The filing states that a 'following number' of shares were purchased but does not specify the exact quantity.

What was the total dollar amount spent on the share repurchase?

The filing does not disclose the total dollar amount of the transaction.

On what date did GSK plc announce this transaction?

GSK plc announced the transaction on December 16, 2025.

Who acted as the broker for this share repurchase?

BNP Paribas SA acted as the broker for the transaction.

What is the nominal value of GSK plc's ordinary shares mentioned in the filing?

The nominal value of the ordinary shares is 31¼ pence.

Filing Stats: 3,070 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-12-16 08:02:36

Filing Documents

From the Filing

IN OWN SHARES a6546l     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of December 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 15 December 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 230,000 Lowest price paid per share (GBp): 1,810.50p Highest price paid per share (GBp): 1,838.00p Volume-weighted average price paid per share (GBp): 1,825.73p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 13,621,733 ordinary shares.   Following the above purchase, the Company will hold 239,086,577 ordinary shares in treasury and have 4,076,354,506 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,076,354,506. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.87 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     15 December 2025 Investment firm:         BNP Paribas SA   Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   25,960   1,838.00p   1,811.50p   1,824.68p   CHIX   72,172   1,838.00p   1,810.50p   1,825.43p   XLON   131,868   1,838.00p   1,810.50p   1,826.10p   Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   4   1819.5   XLON   15-Dec-2025   08:00:10   20251215159525211   173   1819.5   XLON   15-Dec-2025   08:00:10   20251215159525213   173   1818.5   XLON   15-Dec-2025   08:00:10   20251215159525215   2   1818.5   XLON   15-Dec-2025   08:00:10   20251215159525219   26   181

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.